Is Ocular Therapeutix Inc (OCUL) overvalued? · rev $63.7M
Ocular Therapeutix Inc (OCUL) is a biotechnology company listed on US.
This page asks whether Ocular Therapeutix Inc (OCUL) looks expensive on cached numbers — not a short thesis.
Latest reported OCUL revenue for 2024-12-31 was $63.7M. Net income was -$193.5M. Revenue was up 9.0% from 2023-12-31 to 2024-12-31. OCUL currently screens at market cap $1.76B.
OCUL currently screens at market cap $1.76B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next OCUL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the OCUL stock page for the full model, not this heading.
Not investment advice.